IMiD/CELMoD-induced growth suppression of adult T-cell leukemia/lymphoma cells via cereblon through downregulation of target proteins and their downstream effectors

• Main Authors: Yu Wang, Shunsuke Shimosaki, Emi Ikebe, Hidekatsu Iha, Jun-ichi Yamamoto, Nichole Fife, Tomonaga Ichikawa, Mitsuo Hori, Masao Ogata, Yoshiyuki Tsukamoto, Naoki Hijiya, Masatsugu Moriyama, Shotaro Hagiwara, Shuichi Kusano, Masumichi Saito, Kamruddin Ahmed, Akira Nishizono, Hiroshi Handa, Kazuhiro Morishita
• Format: Article
• Language: English; English
• Published: Frontiers Media SA 2024
• Subjects: R5-920 Medicine (General); RC254-282 Neoplasms. Tumors. Oncology Including cancer and carcinogens; RC633-647.5 Diseases of the blood and blood-forming organs
• Online Access: https://eprints.ums.edu.my/id/eprint/38798/1/ABSTRACT.pdf; https://eprints.ums.edu.my/id/eprint/38798/2/FULL%20TEXT.pdf; https://eprints.ums.edu.my/id/eprint/38798/; https://doi.org/10.3389/fonc.2023.1272528

Adult T-cell leukemia/lymphoma (ATL) is an aggressive T-cell neoplasia associated with human T-cell leukemia virus type 1 (HTLV-1) infection and has an extremely poor prognosis. Lenalidomide (LEN; a second-generation immunomodulatory drug [IMiD]) has been employed as an additional therapeutic option...